Newsroom

OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding

View on PRNewswire - Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for...

OnQuality Pharmaceuticals to Present Preclinical Data for OQL051, a Novel CID Therapeutic, at AACR

- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey at ASCO GU

- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...

OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for [...]

Full Title: OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea...

OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer [...]

Therapy Induced Skin Toxicity that Met Expectations - Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company's...

OnQuality Pharmaceuticals Announces Completion of Part 1 of NOVA-II Trial

- Top-line readout of clinical study results anticipated by the end of 2021 SEATTLE, Sept. 7, 2021 /PRNewswire/ -- OnQuality...

OnQuality Pharmaceuticals Announces Upcoming Presentation at 2021 BIO Digital

SEATTLE, June 9, 2021 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted cancer supportive care company developing...

OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC

OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings SEATTLE, May 19,...

OnQuality Pharmaceuticals Announces Closing of $35 Million Series A and A+ Financing

SEATTLE and SHANGHAI—March 31, 2021. OnQuality Pharmaceuticals LLC ("OnQuality"), a targeted cancer supportive care company developing me...

OnQuality Pharmaceuticals Announces Enrollment of First Patient in a Phase II Study to Evaluate...

Seattle, WA—August 14, 2020. OnQuality Pharmaceuticals (USA) LLC, dedicated to the discovery and development of therapies to improve qua...